Company intelligence / Profile preview

Alcresta Pharmaceuticals

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

RELiZORB is FDA-cleared for use in patients of all ages (including neonates and infants) to hydrolyze fats in enteral formula, addressing fat malabsorption in conditions like cystic fibrosis, short bowel syndrome, and pancreatitis. Next-generation device cleared in 2023, commercially available since May 2024, with expansions in 2025.

Therapeutic areas: OncologyPulmonologyGastroenterology
Modalities: Enzyme replacement therapyDevice
Industry: Biotech

Beyond the preview

Go deeper on Alcresta Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alcresta Pharmaceuticals.

Explore the full profile